CytoSorbents posts investor presentation outlining Q2 revenue, cash burn progress toward breakeven - CTSO News | RalliesCytoSorbents posts investor presentation outlining Q2 revenue, cash burn progress toward breakeven
C
CTSO• DrugSorb-ATR and STAR-T trial update
- DrugSorb-ATR remained investigational in the US, with a new De Novo submission planned to pursue regulatory clearance.
- The pivotal STAR-T randomized trial paper was published, supporting the device’s program in CABG patients recently exposed to ticagrelor.
Q2 revenue, margin and cash burn update
- CytoSorbents posted Q2 2026 revenue of USD 9.6 million, gross margin of 73%, operating cash burn of about USD 200,000.
- Management targeted operating cash flow breakeven in the second half of 2026.
- Core CytoSorb product sales reached a record USD 37.3 million on a trailing 12-month basis through June 30, 2026.
